Amgen On Final Space Shuttle Mission

Thousand oaks-based biotech giant Amgen said Tuesday that the firm is taking part in a preclinical test on the final, NASA Space Shuttle mission scheduled to launch Friday. According to Amgen, it is in a collaboration with UCB and NASA Ames Research Center, to conduct a test of a sclerostin antibody, aimed at assessing its effect on the loss of bone associated with space flight. Bone loss is a big issue for long term spaceflight. Amgen's compound inhibits a protein which results in the loss of bone in the case of "skeletal disuse", which includes such conditions as stroke, cerebral palsy, muscular dystrophy, in addition to space flight.


More Headlines